bosutinib
Sign in to saveAlso known as Bosulif®, SK 606, SK-606, SKI 606, SKI-606, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
Bosutinib, sold under the brand name Bosulif, is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia.
Research
936 papers- Bosutinib.2012
- A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.Blood · 2021
- Bosutinib.2006
- Bosutinib: Pediatric First Approval.Paediatric drugs · 2024
- Bosutinib.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2010
via PubMed
~2 min read
Encyclopedic overview
7 sectionsContents
- Mechanism
- Medical uses
- Contraindications
- Interactions
- Notes
- See also
- References
Bosutinib, sold under the brand name Bosulif, is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia.
Originally synthesized by Wyeth, it is being developed by Pfizer.
Excerpted from Wikipedia’s “bosutinib” article, available under the CC BY-SA 4.0 licence.